What puts your patients with HIV at risk for steatohepatitis or NASH? Review the increasing prevalence of fatty liver disease, the spectrum of disease from NAFLD to NASH, and the overlap in the epidemics of NASH and HIV.
Review the pathogenesis of NASH in patients with HIV, including the role of metabolic comorbidities, long-term ART, and risk factors that contribute to NASH development especially among the aging population.
Learn best practices for screening strategies and diagnosing NASH in patients with HIV.
Learn how and why lifestyle modification, weight reduction, and pharmacotherapy may benefit patients with HIV and NASH.